Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRCT-101SR in Adult ADHD
NCT05683249Phase 3Completed
- Sponsor
- Neurocentria Inc.
- Start
- Feb 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of NRCT-101SR in attention deficit hyperactivity disorder (ADHD), sponsored by Neurocentria Inc.. Started Feb 2023; status: completed.
02
Drugs
NRCT-101SR
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT05683249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05683249.